Disclosed are compounds of the formula
##STR1##
and the pharmaceutically acceptable salts thereof where the variables R1,
R2, A, R4, R5, R6, R6,
n, and W are defined herein. These compounds bind to the benzodiazepine site of
GABAA receptors are provided and, therefore can be used to modulate
ligand binding to GABAA receptors in vivo or in vitro, and are particularly
useful in the treatment of a variety of central nervous system (CNS) disorders
in humans, domesticated companion animals and livestock animals.